Nephros, Inc.
NEPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -0.5% | 42.7% | -2.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 61.6% | 59% | 47.4% | 55.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 0% | -11.2% | -43.5% | -31.8% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | $0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 0.5% | -11.1% | -74% | -40.2% |
| EPS | 0.007 | -0.15 | -0.72 | -0.41 |
| % Growth | 104.7% | 79.2% | -75.6% | – |
| EPS Diluted | 0.007 | -0.15 | -0.72 | -0.41 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 1.6% | -9.5% | -37% | -24.4% |